Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
16.04
-0.33 (-2.02%)
At close: Apr 28, 2026, 4:00 PM EDT
16.04
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Company Description
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases.
The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Kevin Tang |
Contact Details
Address: #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Peter S. Greenleaf M.B.A. | Consultant |
| Michael S. Hearne CPA | Chief Financial Officer |
| Ryan Cole | Chief Operating Officer |
| Thomas Wei | Chief Scientific Officer |
| Andrea Levin Christopher | Executive Director of Corporate Communications and Investor Relations |
| Stewart M. Kroll | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 25, 2026 | SCHEDULE 13D/A | Filing |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 3, 2026 | SCHEDULE 13D/A | Filing |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Nov 4, 2025 | 8-K | Current Report |
| Nov 4, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | SCHEDULE 13D/A | Filing |